Patent US5147646A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5147646A Expired / Lapsed US ⏱️ 0.0 years remaining

Hydrogel containing envelopes

Assignee: BTG International Ltd
•
Filing: 1991-09-16
•
Granted: 1992-09-15
•
Expires: 2011-09-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An envelope having flexible water-permeable or porous walls contains a quantity of particulate water-insoluble hydrogel. The quantity of hydrogel in the envelope is such that, when the hydrogel is fully swollen at 20 DEG C., its volume is at least 66%, preferably at least 100%, of the maximum non-stretched internal volume of the envelope. Thus, the envelope according to the invention is limp and floppy under dry conditions but in a wet environment the hydrogel absorbs water and swells accordingly causing the envelope to swell and take on a more rigid configuration. The envelope is particularly useful for the administration of sustained release pharmaceutically or veterinarily active ingredients. Thus the limp dry envelope may for example be rolled up for introduction through the throat but will swell up and therefore be retained in the stomach for sustained release of the active ingredient therein.

Inventors

  • 👤 Neil B. Graham

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 03:06
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0087; A61K9/009; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; C; C02; C02F; C02F1/00; C02F1/26; C02F1/265; C08; C08G; C08G18/00; C08G18/06; C08G18/28; C08G18/40; C08G18/48; C08G18/4833; C08G18/65; C08G18/66; C08G18/6666; C08G18/667; C08G18/6674; C08G18/6677; C08G2210/00

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 87 words
A method of treating animals which method comprises administering to the animal an envelope having flexible water-permeable or porous walls and a given maximum non-stretched internal volume and containing a quantity of particulate water-insoluble hydrogel and a veterinarily active ingredient in sustained release form in the closed envelope wherein the volume of the quantity of hydrogel when fully swollen at 20° C. amounts to at least 66% of the given maximum non-stretched internal volume but is insufficient when fully swollen at 20° C. to rupture the envelope.
Claim 2
Independent Claim 87 words
A method of treating animals which method comprises administering to the animal an envelope having flexible water-permeable or porous walls and a given maximum non-stretched internal volume and containing a quantity of particulate water-insoluble hydrogel and a veterinarily active ingredient in sustained release form in the closed envelope wherein the volume of the quantity of hydrogel when fully swollen at 20° C. amounts to at least 66% of the given maximum non-stretched internal volume but is insufficient when fully swollen at 20° C. to rupture the envelope.
Claim 3
Dependent Claim 12 words
A method according to claim 1 wherein the animal is a ruminant.
Claim 4
Independent Claim 89 words
A method of treating a human patient which method comprises administering to the patient an envelope having flexible water-permeable or porous walls and a given maximum non-stretched internal volume and containing a quantity of particulate water-insoluble hydrogel and a pharmaceutically active ingredient in sustained release form in the closed envelope wherein the volume of the quantity of hydrogel when fully swollen at 20° C. amounts to at least 66% of the given maximum non-stretched internal volume but is insufficient when fully swollen at 20° C. to rupture the envelope.
Claim 5
Independent Claim 89 words
A method of treating a human patient which method comprises administering to the patient an envelope having flexible water-permeable or porous walls and a given maximum non-stretched internal volume and containing a quantity of particulate water-insoluble hydrogel and a pharmaceutically active ingredient in sustained release form in the closed envelope wherein the volume of the quantity of hydrogel when fully swollen at 20° C. amounts to at least 66% of the given maximum non-stretched internal volume but is insufficient when fully swollen at 20° C. to rupture the envelope.
Claim 6
Independent Claim 124 words
A device for sustained release of an active ingredient in the stomach of a human or animal, which device comprises an envelope having flexible water-permeable and porous walls of perforated plastic, knitted, braid or woven material, the envelope containing particulate water-insoluble hydrogel in a pharmaceutically, veterinarily or biologically active ingredient in sustained release form in the closed envelope wherein the volume of the hydrogel when fully swollen in water at 20° C. amounts to at least 66% of the maximum non-stretched internal volume of the envelope and is sufficient to retain the device within the stomach of the human or animal during the sustained release of the active ingredient but is insufficient when fully swollen in water at 20° C. to rupture the envelope.
Claim 7
Independent Claim 124 words
A device for sustained release of an active ingredient in the stomach of a human or animal, which device comprises an envelope having flexible water-permeable and porous walls of perforated plastic, knitted, braid or woven material, the envelope containing particulate water-insoluble hydrogel in a pharmaceutically, veterinarily or biologically active ingredient in sustained release form in the closed envelope wherein the volume of the hydrogel when fully swollen in water at 20° C. amounts to at least 66% of the maximum non-stretched internal volume of the envelope and is sufficient to retain the device within the stomach of the human or animal during the sustained release of the active ingredient but is insufficient when fully swollen in water at 20° C. to rupture the envelope.
Claim 8
Dependent Claim 31 words
The envelope according to claim 4, wherein the quantity of hydrogel when fully swollen in water at 20° C. amounts to at least 100% of the given maximum non-stretched internal volume.
Claim 9
Dependent Claim 14 words
The envelope according to claim 4, wherein the hydrogel is a crosslinked polyethylene glycol.
Claim 10
Dependent Claim 22 words
The envelope according to claim 4, which contains a mixture of hydrogel particles and particles of active ingredient in sustained release form.
Claim 11
Dependent Claim 20 words
The envelope according to claim 4, wherein the active ingredient in sustained release form is contained in the hydrogel particles.
Claim 12
Dependent Claim 34 words
The envelope according to claim 4, wherein the quantity of hydrogel when fully swollen in water at 20° C. ranges from 90 to 110% of the given maximum non-stretched internal volume of the envelope.
Claim 13
Dependent Claim 27 words
The envelope according to claim 4, wherein the average particle size of the hydrogel particles is at least 1% larger than the pores of the surrounding envelope.
Claim 14
Dependent Claim 24 words
The envelope according to claim 10, wherein said average particle size is at least twice the size of the pores of the surrounding envelope.
Claim 15
Dependent Claim 26 words
The envelope according to claim 4, wherein the hydrogel is one that upon swelling absorbs more than 40% of its dry weight of water without dissolution.
Claim 16
Dependent Claim 21 words
The envelope according to claim 12, wherein the degree of swelling of the hydrogel ranges between 150 and 1000% by weight.
Claim 17
Dependent Claim 14 words
The envelope according to claim 4, which is in the form of a toroid.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1995-09-15 1996-03-16 1996-09-15 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1999-09-15 2000-03-16 2000-09-15 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2003-09-15 2004-03-16 2004-09-15 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag